Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer – phase 1 trial

ConclusionMRgFUS is a feasible and safe method of noninvasively ablating low –intermediate risk PCa with acceptable short-term oncologic outcomes.Key Points•Focal therapy selectively ablates locally confined, clinically significant index lesion with a margin while sparing rest of gland and adjacent vital structures.•Magnetic resonance-guided focused high frequency ultrasound surgery (MRgFUS) combines MRI with HIFU.•MRgFUS provides ability to monitor treatments in real time and allows a targeted approach for focal ablation.•MRgFUS is a feasible, safe method of noninvasively ablating low –intermediate risk PCa.•MRgFUS provides  acceptable oncologic outcomes at 6 months.
Source: European Radiology - Category: Radiology Source Type: research